



COLLABORATIVE WORKING EXECUTIVE SUMMARY

Project Title: Huntington's disease (HD) – Co-production of a proposed new service model for patients in Surrey Heartlands Health and Care Partnership

Project Description

Roche and Kent, Surrey and Sussex Academic Health Science Network (KSSAHSN) propose to work together under a Collaborative Working Agreement to support the production of a service model proposal for Huntington's Disease (HD) in Surrey.

Organisations Involved

Kent Surrey Sussex Academic Health Science Network – Lead: Peter Carpenter, Service Delivery Director.
(Note – KSS AHSN undertaking this work on behalf of Surrey Heartlands CCG following agreement with Jane Williams, Deputy Managing Director of Guildford and Waverly Integrated Care Partnership)
Roche Products Ltd – Lead: Stuart Underhill, Health Systems Partner Community Lead

Project Rationale

The overarching aim of this project is to produce a service model proposal for the care of patients with HD in the Surrey Heartlands Health and Care Partnership, which is aligned with principles of reducing unwarranted variance and the wider determinants of health, for patients, their families and carers.

Specifically; NHS England (NSHE) does not currently have a service specification or a service model for the delivery of care for patients with HD in England. Additionally, there is also no standardised service for HD across Surrey Heartlands. Patient management is varied both locally and nationally. This project will provide an opportunity to build on existing services to develop a service model that provides a standard fit for purpose service providing equitable care for HD patients in Surrey Heartlands. The output of the service model developed as well as the service design process may be used as an example of best practice with other healthcare communities in England.

The improved specification for the model of care developed could deliver the "triple aim" in improvement and innovation; improved clinical effectiveness of provision, improved value for money and improved patient and citizen experience.

Project period

Project Start Date: July 2021

Project End Date: September 2021

Anticipated time for the project – 12 working weeks (excluding holiday period in August)

Project Approach

The project will be delivered in 3 phases.

- Phase 1: Project development and scoping
- Phase 2: Gaining deeper insights, consolidation and co-design
- Phase 3: Development of a proposed new model of care

Project Outcome

This project aims to create a new proposal for a HD service model of care in Surrey Heartlands Health and Care Partnership. The model will present a service design that is aligned with principles of reducing unwarranted variance and the wider determinants of health.

The findings from this collaborative working project will be utilised within Surrey Heartlands Health and Care Partnership, shared with NHSE/I and can be utilised by Roche Products Limited to facilitate discussions for the development of HD models in other areas. It is anticipated that this project will result in publication to help share the learnings more broadly.

Benefit for patients

An opportunity for the patients, their carers and their families in Surrey to offer insights and co-design the care they receive.

The opportunity for new services to be commissioned and funding identified for service improvement. This work could enable other areas to review their own service model and possibly improve services for other conditions.

Benefit to the NHS

Improved understanding of the challenges and possible solutions from the report, which could allow the Integrated Care Systems/Integrated Care Partnerships to enhance both patient experience and outcomes.

Understanding of resourcing levels required to manage the local patient cohort and how best to allocate existing resources to enhance outcomes – delivery of best value services.

Benefit to Roche

An opportunity to partner with the NHS to help develop a new service model proposal for HD services in Surrey.

The opportunity to share the experience of developing the service model with other areas and NHSE.

A better understanding of patients', carers and healthcare professionals' needs.

Identify outcome measures that could be incorporated into clinical development programmes.

This document has been produced by Roche Products Ltd and Kent, Surrey & Sussex AHSN

Date of Preparation June 2021

M-GB-00003886